anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hypoxic exposure increases right ventricular (RV) afterload by triggering pulmonary hypertension, with consequent effects on the structure and function of the RV. Improved myocardial contractility is a critical circulatory adaptation to exercise training. However, the types of exercise that enhance right cardiac mechanics during hypoxic stress have not yet been identified. This study investigated how high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT) influence right cardiac mechanics during hypoxic exercise (HE).

The young and healthy sedentary males were randomly selected to engage in either HIIT (3-min intervals at 40% and 80% of VO2 oxygen uptake reserve) or MICT (sustained 60% of VO2 oxygen uptake reserve) for 30 min/day and 5 days/week for 6 weeks or were included in a control group (CTL) that did not engage in any exercise. Right cardiac mechanics during semiupright bicycle exercise tests under hypoxic conditions (i.e., 50 watts under 12% FiO2 for 3 min) were measured using two-dimensional speckle-tracking echocardiography. The primary outcome was the change in right cardiac mechanics during semiupright bicycle exercise under hypoxic conditions (i.e., 50 watts under 12% FiO2 for 3 min) as measured by two-dimensional speckle tracking echocardiography.
Ketoconazole is a potent inhibitor of the cytochrome P450 (CYP) 3A4 enzyme system, one of the enzyme systems responsible for the metabolism of colchicine. This study will evaluate the effect of multiple doses of ketoconazole on the pharmacokinetic profile of a single 0.6 mg dose of colchicine. A secondary objective is to evaluate the safety and tolerability of this regimen in healthy volunteers. All study subjects will be monitored for adverse events throughout the study period. After a fast of at least 10 hours, twenty-four healthy, non-smoking, non-obese, non-pregnant adult volunteers between the ages of 18 and 45 years will be given one dose of colchicine (1 x 0.6 mg tablet) orally on Day 1. Fasting will continue for 4 hours after the dose. Blood samples will be drawn from all participants before dosing and for twenty-four hours post-dose on a confined basis at times sufficient to adequately define the pharmacokinetics of colchicine. Blood sampling will then continue on a non-confined basis on Days 2-5. On Days 15-18, subjects will return to the clinic daily for non-confined dosing of ketoconazole (1 x 200 mg tablet) twice daily, every 12 hours. Administered ketoconazole doses on these days will not necessarily be in a fasted state. On Day 15, after taking the first dose of ketoconazole, subjects will remain in the clinic for observation for 1 hour post-dose administration. Then, on Day 19, co-administration of a single dose of colchicine (1 x 0.6 mg tablet) and ketoconazole (1 x 200 mg tablet) will occur following a fast of at least 10 hours in subjects confined to the clinic for dosing and 24-hour blood sampling will be performed at times sufficient to adequately determine the pharmacokinetics of colchicine. Blood sampling will continue on a non-confined basis on Days 20-23. Fasting will continue for 4 hours following the co-administered dose of ketoconazole and colchicine. The final dose of ketoconazole (1 x 200 mg tablet) will be administered to subjects the evening of Day 19, in a non-fasting state. A further goal of this study is to evaluate the safety and tolerability of this regimen in healthy volunteers. Subjects will be monitored throughout participation in the study for adverse reactions to the study drug and/or procedures. Vital signs (blood pressure and pulse) will be measured prior to dosing and at 1, 2, and 3 hours following drug administration on Days 1 and 19 to coincide with peak plasma concentrations of both colchicine and ketoconazole. All adverse events whether elicited by query, spontaneously reported, or observed by clinic staff, will be evaluated by the Investigator and reported in the subject's case report form.
Vincristine sulfate can cause fetal harm when administered to a pregnant woman. When pregnant mice and hamsters were given doses of vincristine sulfate that caused resorption of 23% to 85% of fetuses, fetal malformations were produced in those that survived. Five monkeys were given single doses of vincristine sulfate between days 27 and 34 of their pregnancies; 3 of the fetuses were normal at term, and 2 viable fetuses had grossly evident malformations at term. In several animal species, vincristine sulfate can induce teratogenesis as well as embryo death at doses that are nontoxic to the pregnant animal. There are no adequate and well–controlled studies in pregnant women. If this drug is used during pregnancy or if the patient becomes pregnant while receiving this drug, she should be apprised of the potential hazard to the fetus. Women of child–bearing potential should be advised to avoid becoming pregnant.
This study is a 24-weeks, multicenter, randomized, double-blind, double- placebo, parallel controlled phase III trial being carried out in 23 centers around China. The study population includes mild to moderate VaD patients (planned a total of 630) aged 45-85 in both gender. Participants will be randomly allocated to TZK (15g/d) and placebo identified to donepezil, donepezil (5mg/d) and placebo identified to TZK, or placebo identified to TZK and placebo identified to donepezil for a 24-weeks double-blind treatment period . The primary outcome measure is change from baseline in the Vascular Dementia Assessment Scale-Cognitive Subscale and Clinician's Interview-Based Impression of Change-Plus carer Interview. The secondary outcomes are changes from baseline in the Mini-Mental State Examination, Activity of Daily Living Scale, Clock Drawing Test, Trail Making Test and Neuropsychiatric Inventory. Safety is being assessed by observing side effects and adverse reaction during the entire treatment period. Statistical analysis will be conducted according to per-protocol population and intend-to-treat population and the safety will be analyzed in safety set.
FIELD: medicine. SUBSTANCE: method involves determining leukocyte level in blood with laboratory methods. No increase in leukocyte number being observed when compared to norm, patient state is evaluated as secondary immune deficiency and thymalin is administered. Thymalin therapy being over, leukocyte number is counted in 1 ml of blood using a formula KE=L2/L1, where KE is the thymalin treatment effectiveness coefficient, L1 is the leukocyte number in patient blood found in making analysis before thymalin therapy, L2 is the leukocyte number in patient blood found in making analysis after thymalin therapy. KE being ≥ 1.2, the treatment is thought to be effective. EFFECT: simplified reliable method.
Poractant alfa is an extract of natural porcine lung (pulmonary) surfactant consisting of 99% polar lipids (mainly phospholipids) and 1% hydrophobic low molecular weight surfactant associated proteins (SP). The molecular weight of SP-B is 8.7 KDa and the molecular weight of SP-C is 3.7 KDa.

CUROSURF (poractant alfa) intratracheal suspension is a sterile, white to creamy white suspension provided in a single-dose vial for intratracheal use. Each milliliter of suspension contains 80 mg of poractant alfa (surfactant extract) that includes 76 mg of phospholipids and 1 mg of SP of which 0.45 mg is SP-B, a 79-amino acid protein and 0.59 mg is SP-C, a 35-amino acid peptide . The amount of phospholipids is calculated from the content of phosphorus and contains 55 mg of phosphatidylcholine of which 30 mg is dipalmitoylphosphatidylcholine. It is suspended in 0.9% sodium chloride solution. The pH is adjusted with sodium bicarbonate to a pH of 6.2 (5.5 to 6.5).

Curosurf contains no preservatives.
The present invention relates to the technical field of medicines. Disclosed are a synthetic peptide and an application thereof. The chemical formula of the synthetic peptide is (Gly)x-(beta-Ala-L-His)y-(Gly)z, (Gly)x-(beta-Ala-L-1-Methyl-His)y-(Gly)z or (Gly)x-(beta-Ala-L-3-Methyl-His)y-(Gly)z; y being equal to or greater than 1, and x and z being 0-3 and being not both equal to zero. A specific peptide can also have beta-Ala-L-His, beta-Ala-L-1-Methyl-His, or beta-Ala-L-3-Methyl-His simultaneously. In the synthetic peptide in the present invention, glycine, carnosine, anserine, ophidine or the like are creatively combined, and the developed mosaic synthetic peptide unexpectedly penetrates the blood-brain barrier to enter the brain by means of intravenous injection and effectively plays a role in treating nervous system diseases. In the present invention, a remarkable treatment effect can be achieved using only 3 mg/kg of synthetic polypeptide intravenous injection dosage.
PURPOSE:To obtain an amino acid derivative useful as a therapeutic agent for cardiac insufficiency industrially and advantageously by a new method for using a hemiacetal substance prepared by electrically oxidizing a pipecolic acid derivative as an intermediate. CONSTITUTION:A pipecolic acid derivative of formula I (R<3> to R<5> are H, OH, etc.; R'' is a carboxylic acid-protecting group; Z is an acyl or carbamate) is electrically oxidized preferably by a method for using platinum or carbon as an electrode and tetraethylammonium perchlorate as a supporting electrolyte and injecting >=2 Faraday s/mol to the compound of formula I to give a hemiacetal substance of formula II (R<12> forms an aldehyde equivalent with an N atom in the ring) and the objective compound is obtained from the hemiacetal substance. The hemiacetal substance is reacted with a cysteine derivative of formula III (R<2> is H or a carboxylic acid protecting group; R<6> and R<7> are each H, a lower alkyl, etc.) to give a thiazolidine derivative. Then, the compound is deprotected and subjected to ring formation to give an amino acid derivative of formula IV.
Like RAP Club, Healthy Topics is a 12-session program delivered twice per week over six weeks during the school day. The program is delivered by a trained facilitator and young adult community member.
After informing the individuals who applied to the urology service for TURP or TURM about the study, the researcher will receive their informed consent in written form. The information required for the study of the patients in the control group 1 day before the operation will be recorded in the Patient Information Form by the service nurse. On the morning of the surgery, the RCSQ will be applied to the patients to determine the preoperative sleep quality and the Patient follow-up form will be applied to determine the confounding factors that may affect sleep. In the morning of the first day after the surgery, the RCSQ will be applied to the patients to determine the sleep quality on the postoperative day 0, and the Patient follow-up form will be applied to determine other possible factors that may affect sleep, and the data collection process of the study will be terminated. No foot bath application will be in question for the patients in the control group.
Participants will receive a web link to a library of 4 PE videos. These brief 2-minute videos include general information about self-care during college.
The primary objective of the proposed study is to determine the potential role of Ketamine as an analgesic agent in pediatric sickle cell disease patients with refractory symptoms in acute (VOC). Our study design is as follows: Prospective observational study of 20 pediatric sickle cell disease patients with refractory pain to conventional analgesic regimens seen in the pediatric emergency medicine department. Consenting patients with refractory pain meeting inclusion criteria will be given a single intravenous bolus of Ketamine at a set dosage of 0.25 milligrams per kilogram of weight. Participants' perception of pain will then be recorded using standard pain scoring scales (FLACC score). Physiologic criteria such as heart rate, blood pressure, blood oxygen saturation, total analgesic pharmacologic requirements for adequate analgesia during hospitalization, and duration of hospitalization will be measured. Observational study group will continue to get standard of care outside of single bolus of Ketamine. 48 hour follow up after hospital discharge will be obtained to assess degree of pain control and general clinical status.
The aging process is associated with the development of a wide range of degenerative disorders in mammals. These diseases are characterized by a progressive decline in function at multiple levels, including the molecular, cellular, tissue, and organismal. Furthermore, it is responsible for various healthcare costs in developing and developed countries. Sarcopenia is the deterioration in the quality and functionality of muscles, which is extremely concerning as it manages many functions in the human body. This article reviews the molecular crosstalk involved in sarcopenia and the specific roles of many mediator molecules in establishing cross-talk between muscles, bone, and fatty tissues, eventually leading to sarcopenia. Besides, the involvement of various etiological factors, such as neurology, endocrinology, lifestyle, etc., makes it exceedingly difficult for clinicians to develop a coherent hypothesis that may lead to the well-organized management system required to battle this debilitating disease. The several hallmarks contributing to the progression of the disease is a vital question that needs to be addressed to ensure an efficient treatment for sarcopenia patients. Also, the intricate molecular mechanism involved in developing this disease requires more studies. The direct relationship of cellular senescence with aging is one of the pivotal issues contributing to disease pathophysiology. Some patented treatment strategies have been discussed, including drugs undergoing clinical trials and emerging options like miRNA and protein-enclosed extracellular vesicles. A clear understanding of the secretome, including the signaling pathways involved between muscles, bone, and fatty tissues, is extremely beneficial for developing novel therapeutics for curing sarcopenia.
PURPOSE: To obtain a non-emulsified type tip overcoat capable of preventing rouge from sticking on e.g. a cup and excellent in the function to improve the color sustainability of rouge, comprising a metallic soap and/or acylated amino acid, a polyhydric alcohol and water. CONSTITUTION: This lip overcoat is obtained by incorporating water with a total of pref. 0.025-90 (esp. 1-70)wt.%, based on the whole lip overcoat, of a metallic soap of formula (RCOO)2 M (R is a 10-24C aliphatic hydrocarbon; M is a metal except Na, K, Rb, Cs and Fr) (e.g. zinc laurate) and/or an acylated amino acid (esp. pref. lauroyllysine) and a polyhydric alcohol (pref. glycerin). Formulation of a water-soluble polymer (e.g. gum arabi, xanthane gum, methyl cellulose) in the above active ingredients improves the usability of this lip overcoat. Being liquid, this lip overcoat is easy to apply, impairing no rouge texture.
Participants will undergo the same exercise program as described in the exercise only treatment arm. Participants will receive equal contact supplemental individual manualized strategies each session (+15-20 minutes) centered on behaviour change strategies (i.e., action planning, implementation intentions, relapse prevention, and goal setting).
The 35% hydrogen peroxide gel will be mixed and applied over the buccal surfaces of teeth. The bleaching agent will remain for 45-min application without replacement of peroxide.
The present invention discloses a medicine for treating functional dyspepsia and pedo-anorexia diseases. The present invention uses fresh Chinese herbal medicine-hippophae rhamnoides as raw material, and is made by the steps of squeeze, raw juice concentration, separation, oil extraction, pelletization, dryness, split charging, etc. By dissolving juice and oil into a whole, hippophae rhamnoides dry emulsion is made. Thus, active components in the hippophae rhamnoides are maintained, and fat-soluble medicine therapeutic effect and disease curative ratio are also enhanced. The present invention has the efficacy of dyspepsia relieving, blood circulation promotion, mark dispersing and qi regulation to alleviate pain. The medicine for treating functional dyspepsia and pedo-anorexia diseases is used for treating dyspepsia and the symptoms of stomach and belly swelling pain, poor appetite, anorexia, nausea and vomit, etc. caused by pedo-anorexia. The present invention has the advantages of convenient carrying and taking, easy preservation and transportation, stable quality, outstanding treating effect, etc.
TITLE OF THE INVENTION            ABSTRACT OF THE DISCLOSURE       Virginiamycin M1 having the Formula:       and virginiamycin M1 analogs having the Formulae I-IV:                     (I)                 (II)                 (III)                 (IV) Virginiamycin M1 and the analogs I-IV are antagonists of cholecystokinin (CCK) and gastrin. Cholecystokinin antagonists are useful as analgesics and in the treatment and prevention of disorders of the gastrointestinal, central nervous and appetite regulatory systems in animals, especially humans. Gastrin antagonists are useful in blocking the receptors for gastrin in humans and may function as agents for the treatment of ulcers, tumors or other gastrointestinal disorders.  The compounds of Formulae I-IV are also antibiotics and are useful as antimicrobial agents in animals including man and are useful as food additives to promote feed utilization in animals.  Virginiamycin Ml and the analogs of Formula I, III and IV are produced by the controlled aerobic fermentation of a strain of Streptomyces olivaceus, ATCC No. 53527, while the analog of Formula II is produced by chemical synthesis.
Placebo will be given to participants incrementally during a 2 week run in period such that they will receive the same amount of pills as the experimental group. During bed rest, participants will be given the same amount of pills and given at the same time of day (morning and evening) as the experimental group. This strategy will occur during four consecutive days of bed rest.
INTRODUCTION: Sexually transmitted infections (STIs) cause considerable morbidity worldwide and, depending on the specific pathogen, may lead to serious complications in the female reproductive tract. Incarcerated women are particularly vulnerable to health problems with a disproportionate high rate of STIs, including infections with human papillomavirus (HPV).
METHODS: Here, cervical swab samples collected from 299 women (18 to 64 years) living in one of the women's prisons of São Paulo, Brazil were submitted for liquid-based cytology to determine the prevalence of precancerous lesions. Furthermore, direct detection of 30 genital HPV genotypes (18 high-risk and 12 low-risk types) and 11 additional STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, Herpes simplex virus 1 and 2, Haemophilus ducreyi, Mycoplasma genitalium and hominis, Treponema pallidum, Trichomonas vaginalis, Ureaplasma parvum and urealyticum) were performed by molecular typing using two PCR-based DNA microarray systems, i.e., EUROArray HPV and EUROArray STI (EUROIMMUN), respectively.
RESULTS: The overall prevalence of cytological abnormalities was 5.8%, including five women with low-grade and five women with high-grade squamous intraepithelial lesions. The overall prevalence of HPV was 62.2, and 87.1% of the HPV-positive women were infected with oncogenic high-risk (HR) HPV types. HPV types 16 (24.1%), 33 and 52 (both 10.4%) were the most frequently detected. The prevalence of the other STIs was 72.8%. Up to four different pathogens were found in the infected women, the most frequent being Ureaplasma parvum (45.3%), Mycoplasma hominis (36.2%) and Trichomonas vaginalis (24.8%).
CONCLUSION: The high number of HR-HPV infections and other STIs described here highlights the fact that the Brazilian female prison population requires more attention in the country's health policies. The implementation of screening programs and treatment measures might contribute to a decrease in the incidence of STIs and cervical cancer in this vulnerable population. However, for such measures to be effective, further studies are needed to investigate the best practice to get more women to engage in in-prison prevention programs, e.g., through offering further sexual health education and self-sampling.
Pregnant women receive (as the intervention) a single oral dose of stable isotope labeled 25(OH)D3. The same women are followed-up in lactation to repeat the same protocol.
INTRODUCTION: Type IV-A choledochal cyst (CDC) has been considered to have a poor prognosis due to the high incidence of postoperative anastomotic strictures and intrahepatic stones. This study aimed to evaluate the surgical outcomes of children with type IV-A CDC and to provide insights for clinical diagnosis and treatment.
METHODS: The study retrospectively analyzed patients from June 2015 to December 2018 at our center, 76 children were diagnosed with type IV-A CDC. All patients underwent single-incision laparoscopic choledochal cyst excision and Roux-en-Y hepaticojejunostomy. The decision to perform ductoplasty was made by comprehensively considering the intrahepatic duct dilatation (IHDD) and stricture. All patients were followed up 1, 3, and 6 months postoperatively, and then every 1 year thereafter. Patients were categorized into two groups based on IHDD changes postoperatively: the long-term group (LTG), with IHDD persisting for over a year, and the short-term group (STG), where IHDD normalized within a year. Single/multiple factor logistic regression was used to analyse the factors influencing postoperative IHDD.
RESULTS: The median follow-up period was 80 months, with a range from 64 to 101 months. The decrease in postoperative liver function parameters, compared to preoperative levels, was statistically significant. Two patients (2.63%) developed bile leaks. One patient (1.32%) developed anastomotic stricture. All patients' IHDD returned to normal size. Fifty-six (73.7%) patients showed normalization of IHDD within one-year postoperatively. The median recovery time for IHDD in patients was 1.65 months, ranging from 3 days to 74 months postoperatively. There were significant differences in intrahepatic biliary sludge and stones and maximum diameter of IHDD between STG and LTG. Logistic regression was used to analyse the factors and found that intrahepatic biliary sludge and a wider maximum diameter of IHDD were risk factors for postoperative long-term IHDD in patients.
CONCLUSION: Single-incision laparoscopic hepaticojejunostomy with selective ductoplasty are safe and effective for children with Type IV-A CDC. Long-term follow-up is recommended for children presenting with intrahepatic biliary sludge and larger IHDD.
Clinical deterioration (CD) is the physiological decompensation that incurs care escalation, protracted hospital stays, or even death. The early warning score (EWS) calculates the occurrence of CD based on five vital signs. However, there are limited reports regarding EWS monitoring in smart home settings. This study aims to design a CD detection system for health monitoring at home (HM@H) that automatically identifies unstable vital signs and alarms the medical emergency team. We conduct a requirement analysis by interviewing experts. We use unified modeling language (UML) diagrams to define the behavioral and structural aspects of HM@H. We developed a prototype using a SQL-based database and Python to calculate the EWS in the front end. A team of five experts assessed the accuracy and validity of the designed system. The requirement analysis for four main users yielded 30 data elements and 10 functions. Three main components of HM@H are the graphical user interface (GUI), the application programming interface (API), and the server. Results show the possibility of using unobtrusive sensors to collect smart home residents' vital signs and calculate their EWS scores in real-time. However, further implementation with real data, for frail elderly and hospital-discharged patients is required.